Sign In
Buy CGEN
$2.34
-0.0700 (-2.90%)
At Close: Aug 10, 2026
Compugen: Better Runway Ahead Of MAIA
11:59pm, Thursday, 06'th Aug 2026
Compugen has improved and now has a more forgiving runway into 2029. This should carry it through MAIA's interim analysis. In my view, MAIA remains the main value driver, which is why CGEN's runway ma
Compugen Ltd. (CGEN) Q2 2026 Earnings Call Transcript
10:59am, Monday, 03'rd Aug 2026
Compugen Ltd. (CGEN) Q2 2026 Earnings Call Transcript
Compugen Q2 Earnings Call Highlights
10:06am, Monday, 03'rd Aug 2026
Compugen NASDAQ: CGEN said its second-quarter 2026 progress included continued enrollment in its MAIA-ovarian study of COM701, advancing partner-led programs with AstraZeneca and Gilead, and a cash ru
Compugen (CGEN) Reports Q2 Loss, Misses Revenue Estimates
09:05am, Monday, 03'rd Aug 2026
Compugen (CGEN) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.08 per share a year ago.
Compugen Reports Second Quarter 2026 Results
07:00am, Monday, 03'rd Aug 2026
COM701 MAIA-ovarian trial progressing as planned with median progression-free survival data from the interim analysis expected by Q1 2027 Trial-in-progress poster on MAIA-ovarian presented at the ESMO
Compugen to Participate in BTIG Biotechnology Conference 2026
07:00am, Tuesday, 21'st Jul 2026
HOLON, Israel, July 21, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, t
Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026
07:00am, Monday, 20'th Jul 2026
HOLON, Israel, July 20, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI
Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress
07:00am, Thursday, 18'th Jun 2026
HOLON, Israel, June 18, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/
Compugen Ltd. (CGEN) Discusses End-to-End AI-Driven Target Discovery in Immuno-Oncology Transcript
01:12pm, Monday, 15'th Jun 2026
Compugen Ltd. (CGEN) Discusses End-to-End AI-Driven Target Discovery in Immuno-Oncology Transcript
Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026
07:00am, Thursday, 11'th Jun 2026
HOLON, Israel, June 11, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery po
Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development
07:00am, Monday, 08'th Jun 2026
HOLON, Israel, June 8, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, to
Compugen: 'Buy' As Early Gastric Cancer Data Reinforces Rilvegostomig Program
08:17am, Tuesday, 19'th May 2026
Compugen (CGEN) is maintained at a "Buy" rating, driven by advancing clinical programs and upcoming catalysts in oncology. Rilvegostomig, partnered with AstraZeneca, is being evaluated in 11 phase 3 s
Compugen Ltd. (CGEN) Q1 2026 Earnings Call Transcript
12:00pm, Monday, 18'th May 2026
Compugen Ltd. (CGEN) Q1 2026 Earnings Call Transcript
Compugen Q1 Earnings Call Highlights
10:09am, Monday, 18'th May 2026
Compugen NASDAQ: CGEN said it remains on track to report interim progression-free survival data in the first quarter of 2027 from its MAIA-ovarian study, as the clinical-stage immuno-oncology company
Compugen (CGEN) Reports Q1 Loss, Lags Revenue Estimates
10:00am, Monday, 18'th May 2026
Compugen (CGEN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.08 per share a year ago.
